A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre, phase III clinical study to evaluate the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P. (Tetravalent) of M/s Cadila Healthcare Limited in healthy children aged 6 months to 17 years

Trial Profile

A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre, phase III clinical study to evaluate the immunogenicity and safety of Inactivated Influenza vaccine (split virion) I.P. (Tetravalent) of M/s Cadila Healthcare Limited in healthy children aged 6 months to 17 years

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 13 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top